Craig-Hallum Initiates Coverage On Acasti Pharma with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and a price target of $6.
February 07, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acasti Pharma receives a Buy rating and a $6 price target from Craig-Hallum, indicating a positive outlook.
The initiation of coverage by Craig-Hallum with a Buy rating and a $6 price target suggests a strong positive outlook for Acasti Pharma. This endorsement by a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100